Last reviewed · How we verify
CDX-1127
At a glance
| Generic name | CDX-1127 |
|---|---|
| Also known as | Varlilumab |
| Sponsor | Craig L Slingluff, Jr |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC (PHASE1)
- Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (PHASE2)
- Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer (PHASE2)
- DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (PHASE2)
- A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma (PHASE1, PHASE2)
- A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) (PHASE1)
- Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (PHASE1, PHASE2)
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CDX-1127 CI brief — competitive landscape report
- CDX-1127 updates RSS · CI watch RSS
- Craig L Slingluff, Jr portfolio CI